NodeAI attains oversubscribed pre-seed funding round

NodeAI attains oversubscribed pre-seed funding round to advance AI-driven lung cancer staging

HAMILTON, ON | January 25, 2025 – NodeAI, a Canadian medical technology startup focused on AI-enabled lung cancer diagnostics, is proud to announce the successful close of its first pre-seed funding round, which was oversubscribed. This milestone marks a significant step forward in NodeAI’s mission to improve the accuracy, efficiency, and consistency of lung cancer staging through real-time artificial intelligence.

The pre-seed funding will enable NodeAI to move closer to their mission of improving the accuracy and efficiency of lung cancer staging through AI. It allows them to accelerate regulatory and product development, advance regulatory readiness, and prepare for upcoming clinical trials as well as, while expanding their team.

“Closing our first round and seeing it exceed expectations is a powerful validation of both the clinical need and the strength of our team,” said Mackensey Bacon, CEO of NodeAI. “This support allows us to move faster toward delivering technology that meaningfully improves lung cancer staging and, ultimately, patient outcomes.”

Founded in 2023, NodeAI was built to address one of the most persistent challenges in lung cancer care: inaccurate or inconclusive staging. Nearly 40% of EBUS-TBNA procedures result in non-diagnostic findings, often leading to repeat biopsies, delayed treatment, and added risk for patients. NodeAI’s cloud-based platform integrates seamlessly into existing clinical workflows to support clinicians without disrupting care.

“This funding enables us to deepen our AI capabilities while maintaining our core philosophy that AI should augment, not replace, clinical expertise,” said Dr. Anthony Gatti, Co-Founder and Chief Technical Officer. “We are building technology that clinicians can trust in high-stakes environments.”

NodeAI’s growth has been supported by Canada’s health innovation ecosystem, including strong academic and clinical partnerships. The company has participated in programs such as McMaster University’s Innovation Matchmaking Program, received investment from the McMaster Seed Fund, and earned recognition through competitive cancer innovation awards. As NodeAI moves into its next phase, the team remains focused on rigorous clinical validation, regulatory excellence, and building Canadian-developed medical AI that can scale globally.

“This is just the beginning,” states Dr. Wael Hanna, co-founder and CMO. “Our goal is clear: to democratize high-quality lung cancer staging and ensure more patients receive the right diagnosis at the right time.”

About NodeAI

NodeAI is revolutionizing lung cancer staging with AI-powered, real-time malignancy predictions at the bedside. The company’s technology ensures optimal treatment decisions and improved patient care through accurate lymph node evaluation for non-small cell lung cancer patients.

This Press Release was originally published by Node AI. Read the original release here.